Point72 DIFC Ltd Invests $118,000 in Perspective Therapeutics, Inc. (NYSE:CATX)

Point72 DIFC Ltd bought a new stake in Perspective Therapeutics, Inc. (NYSE:CATX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 11,842 shares of the company’s stock, valued at approximately $118,000.

Several other hedge funds have also bought and sold shares of CATX. Janus Henderson Group PLC purchased a new stake in shares of Perspective Therapeutics in the 1st quarter valued at $15,511,000. Affinity Asset Advisors LLC purchased a new position in shares of Perspective Therapeutics in the first quarter worth about $6,069,000. Vanguard Group Inc. increased its holdings in shares of Perspective Therapeutics by 34.6% in the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after buying an additional 4,566,356 shares during the period. Ally Bridge Group NY LLC purchased a new stake in Perspective Therapeutics during the 2nd quarter valued at about $3,951,000. Finally, WealthPLAN Partners LLC bought a new position in Perspective Therapeutics during the 2nd quarter worth approximately $1,695,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Stock Performance

NYSE CATX opened at $12.59 on Wednesday. Perspective Therapeutics, Inc. has a 12 month low of $2.20 and a 12 month high of $19.05. The business has a 50 day simple moving average of $13.81.

Perspective Therapeutics (NYSE:CATX) last posted its earnings results on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04. The business had revenue of $0.53 million during the quarter. As a group, equities analysts forecast that Perspective Therapeutics, Inc. will post -0.86 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on CATX shares. Wedbush started coverage on Perspective Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $25.00 target price for the company. Bank of America initiated coverage on shares of Perspective Therapeutics in a research note on Thursday, July 25th. They set a “buy” rating and a $24.00 target price for the company. Oppenheimer reduced their price objective on Perspective Therapeutics from $19.00 to $17.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Finally, Truist Financial assumed coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 target price on the stock. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $20.71.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.